Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Interleukin-21 Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin-21 Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin-21 (IL-21) is a potent cytokine belonging to the class of immunoregulatory molecules known as interleukins. It plays a crucial role in modulating the immune system and has garnered significant interest in medical research for its diverse immunomodulatory properties. IL-21 is mainly produced by activated CD4+ T cells and natural killer T cells, and it exerts its effects by binding to specific receptors on target cells, initiating a cascade of immune responses. IL-21 acts through a receptor complex composed of the IL-21 receptor (IL-21R) and the common gamma chain (γc), which is shared with other cytokines. Upon binding to its receptor complex, IL-21 activates the Janus kinase (JAK) and signal transducer and activator of the transcription (STAT) pathway, leading to the activation of various downstream signaling pathways, culminating in the regulation of immune cell functions. IL-21 holds therapeutic potential for multiple diseases. It is being explored in cancer immunotherapy, particularly in treating solid tumors and hematological malignancies, owing to its ability to enhance antitumor immune responses. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, with around 10 million deaths reported in 2020. IL-21's application in cancer research shows promising results in combatting this global health challenge. Extensive research is being conducted globally to discover new and novel molecules to be used, like Denenicokin, which is used to treat many indications like Autoimmune diseases. The development and launch of new products will thus increase the market's revenue in the forecasted years.
Many of these are in the market, while many are in ongoing clinical trials. 6 companies have 4 IL-21 Agonists in various stages of clinical trials – 1 in Phase 1 of the clinical trials, while 5 companies have 5 IL-21 Inhibitors in different stages of clinical trials – 3 products in Phase 2 and 2 in Phase 1 of the clinical trials
Clinical Activity and Developments of Interleukin-21 (IL-21)
As of July 2023, 6 companies have approximately 4 IL-21 Agonists for various diseases, while 5 have approximately 5 IL-21 Inhibitors for 13 conditions. For these diseases, 3 and various trials, respectively, are being conducted by players globally. For instance,
Drugs in the Pipeline of IL-21 Agonists
|
Molecule name |
Number of studies |
|
denenicokin (BMS-982470) |
2 |
|
JS014 |
1 |
|
hV01 |
1 |
|
latikafusp (AMG 256) |
1 |
Drugs in the Pipeline of IL-21 Inhibitors
|
Molecule name |
Number of studies |
|
NN9828 |
6 |
|
avizakimab (BOS161721) |
2 |
|
ATR-107 |
1 |
|
LY3200327 |
1 |
|
tofacitinib/fingolimod (FMX114) |
1 |
IL-21, a powerful immunoregulatory cytokine, has a broad range of indications in medical research, with some applications showing particular assurance. One of the most significant areas where IL-21 finds use is in cancer immunotherapy. It has been extensively studied for its potential to enhance the immune response against various cancers, including melanoma, renal cell carcinoma, and lymphoma. Additionally, IL-21 plays a crucial role in treating viral infections, such as chronic hepatitis B and C, by stimulating antiviral immune responses. The cytokine's immunomodulatory properties are also explored in autoimmune diseases like type 1 diabetes and systemic lupus erythematosus, which aims to restore immune balance. Furthermore, IL-21 is being investigated as an adjuvant for vaccines, aiming to improve the effectiveness of vaccination strategies against infectious diseases. As research into IL-21 continues, its versatile applications offer hope for innovative therapeutic approaches across multiple medical fields.
The prevalence of Renal Cell Carcinoma (RCC) has been on the rise globally, affecting hundreds of thousands of individuals annually. It is estimated that there are approximately 400,000 new cases of RCC recorded every year across the world, with the United States of America contributing a significant number of 82,000 new cases annually. Notably, the highest prevalence of RCC has been reported in the Czech Republic and North America, with varying prevalence rates across different regions. According to research findings, Systemic Lupus Erythromaticus (SLE) has affected roughly 400,000 people globally every year, with a global incidence rate of 5.14 per 100,000 individuals and a prevalence rate of 3.41 million people. However, the incidence of this disease varies significantly across different populations and regions, with most of the patients being women. The rising incidence rates of these diseases present a unique opportunity for players in the global market to come up with effective solutions to combat these health conditions.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Currently, no IL-21 Agonist and IL-21 Inhibitor have been approved by the FDA.
These are used to treat diseases caused by various diseases like autoimmune diseases including SLE, Crohn's disease, Rheumatoid Arthritis, Hepatitis B and C, and others.
BMS, Shanghai Junshi Bioscience, Anwita Bioscience, ConVerd Pharmaceuticals, and Amgen are major market players for IL-21.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and rising incidence of various diseases like SLE, Crohn's disease, Rheumatoid Arthritis, and others are the key opportunities for IL-21 in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.